Just weeks after Unimed became the first activated center in Europe to participate in an international Phase 3 clinical trial evaluating the efficacy and safety of ruxolitinib cream in patients with hidradenitis suppurativa (HS), we are proud to announce another success.
The Unimed team has achieved the impressive feat of becoming the first centre in Europe to successfully screen and randomise a patient in this study.This achievement is particularly significant as patient recruitment in such international clinical trials is competitive between activated centres, and the rapid enrolment of the first participant places Unimed among the leading and most active study sites in Europe.
All of this is the result of a high level of dedication and coordination between all team members, from the researchers to the coordinators and nurses. Thanks to the joint efforts and impeccable organization, Unimed is consolidating its position as one of the leading clinical research centers in the region.
Congratulations to the entire team who, with perseverance and commitment, continue to contribute to the advancement of medical science and the access of Bulgarian patients to innovative therapies!
Contact us for a consultation, research information or partnership. We will assist you with care and professionalism.
